in chronic progressive multiple sclerosis, we would like to point out that 10 years ago we published in Chile,2 a report on the subject. We In vitro experimentation provides us with no expectation of antimyotonic action from calcium channel blockers. Nifedipine (up tp 30uM), and nicardipine (up to 50MM) have proven ineffective as antimyotonic agents in the rat diaphragm made myotonic by blocking C1-channels with either, 2,4-dichlorophenoxyacetates or with anthracene-9-carboxylate (unpublished observations). It can be inferred that Ca' + channels were blocked in these experiments without effect on the myotonia since nifedipine (5yM) is known to block Ca ++ channels in rat extensor digitorum longus muscle.6 As added proof, Ca'+ channels are similarly blocked by Cd+ + (0 1-1 mM)6 but Cd + + at these concentrations also blocks Cl-channels and is a powerful inducer of myotonia,2 the attendant absencs of Ca+ + conductance notwithstanding.
Finally, it needs to be remembered that myotonic stiffness is seldom a major concern of patients with myotonic dystrophy who are much more likely to be debilitated by other aspects of their disease. Treatments for myotonia, then, must prove less of a nui-4' sance than the myotonia itself and must not aggravate other symptoms of the disease. Cardiac conduction abnormalities are frequent in myotonic dystrophy7 and calciunl channel blockers are known to have adverse effects on conduction.8 Other adverse reactions to these agents are also common.9
Considerably better clinical, experimental and theoretical evidence of nifedipine's efficacy as an antimyotonic agent would need to be presented before I was convincev that it had any benefits to weigh against itl disadvantages. Other treatments, backed up by success in double blind trials, supported by in vitro studies and soundly theoretically based, are available. 2 4 
